Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 137

1.

Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study.

Amini E, Palmer TC, Cai J, Lieskovsky G, Daneshmand S, Djaladat H.

World J Urol. 2018 Aug;36(8):1233-1239. doi: 10.1007/s00345-018-2266-y. Epub 2018 Mar 13.

PMID:
29536157
2.

Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.

Djaladat H, Amini E, Xu W, Cai J, Daneshmand S, Lieskovsky G.

Prostate. 2017 May;77(7):743-748. doi: 10.1002/pros.23306. Epub 2017 Feb 1.

PMID:
28144967
3.

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

Shahabi A, Satkunasivam R, Gill IS, Lieskovsky G, Daneshmand S, Pinski JK, Stern MC.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E17-22. doi: 10.5489/cuaj.3163. Epub 2016 Jan 14.

4.

Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.

Fairey AS, Daneshmand S, Skinner EC, Schuckman A, Cai J, Lieskovsky G.

Urol Oncol. 2014 Feb;32(2):85-91. doi: 10.1016/j.urolonc.2013.03.005. Epub 2013 Oct 30.

PMID:
24183191
5.

Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy.

Fairey AS, Daneshmand S, Wang L, Schuckman A, Lieskovsky G, Djaladat H, Cai J, Miranda G, Skinner EC.

Urol Oncol. 2014 Feb;32(2):110-6. doi: 10.1016/j.urolonc.2012.04.020. Epub 2013 Mar 14.

PMID:
23499168
6.

Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.

Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC.

Urol Oncol. 2013 Nov;31(8):1737-43. doi: 10.1016/j.urolonc.2012.07.005. Epub 2012 Nov 7.

PMID:
23141776
7.

Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.

Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S.

Urol Oncol. 2013 Nov;31(8):1441-7. doi: 10.1016/j.urolonc.2012.03.006. Epub 2012 Apr 18.

PMID:
22516714
8.

Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.

Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O.

Eur Urol. 2012 Jul;62(1):55-63. doi: 10.1016/j.eururo.2012.03.006. Epub 2012 Mar 21.

PMID:
22445223
9.

Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era.

Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G.

Urology. 2012 Mar;79(3):626-31. doi: 10.1016/j.urology.2011.09.051. Epub 2012 Jan 13.

PMID:
22245303
10.

Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy.

Birkhahn M, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG, Cote RJ.

BJU Int. 2011 Sep;108(5):660-4. doi: 10.1111/j.1464-410X.2010.09978.x. Epub 2011 Jan 12.

11.

Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy.

Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA.

BJU Int. 2008 Nov;102(9):1086-91. doi: 10.1111/j.1464-410X.2008.07780.x. Epub 2008 Jul 29.

12.

Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.

Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J.

Hum Pathol. 2007 Oct;38(10):1547-52. Epub 2007 Jul 19.

PMID:
17640713
13.

Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer.

Stein JP, Penson DF, Cai J, Miranda G, Skinner EC, Dunn MA, Groshen S, Lieskovsky G, Skinner DG.

J Urol. 2007 Mar;177(3):876-81; discussion 881-2.

PMID:
17296365
14.

Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer.

Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG.

J Urol. 2006 Nov;176(5):2025-31; discussion 2031-2.

PMID:
17070244
15.

Detection of occult lymph node metastases in locally advanced node-negative prostate cancer.

Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ.

J Clin Oncol. 2006 Jun 20;24(18):2735-42.

PMID:
16782914
16.

Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.

Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J.

Urology. 2006 Jun;67(6):1247-52. Epub 2006 May 12.

PMID:
16697447
17.

A critical analysis of perioperative mortality from radical cystectomy.

Quek ML, Stein JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P, Skinner EC, Lieskovsky G, Skinner DG.

J Urol. 2006 Mar;175(3 Pt 1):886-9; discussion 889-90.

PMID:
16469572
18.

Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.

Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn DI, Ramsey EW.

J Urol. 2005 Nov;174(5):1808-13; discussion 1813.

PMID:
16217292
19.

Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients.

Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG.

Cancer. 2005 Jul 1;104(1):36-43.

20.

Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability.

Quek ML, Barry P, Stein JP, Lieskovsky G, Ginsberg DA.

Urology. 2005 May;65(5):964-7.

PMID:
15882732

Supplemental Content

Loading ...
Support Center